Yongchang Zhang
Changsha, Hunan, 410013, China
Location status: Recruiting
Recruiting
NCT Number: NCT04324125
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
Main enrolled criteria:
Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- HER 2 Insertion or Amplification
- First Diagnosis and Treatment
- Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion criteria
- Patients received antitumor treatment before
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Treatment and study plan
Primary outcomes
-
PFS
Time frame: may 2020- may 2021 (1 year)
Progression free survival
Secondary outcomes
-
OS
Time frame: may 2020- may 2021 (1 year)
Overall survival
-
ORR
Time frame: may 2020- may 2021 (1 year)
To measure the patients's overall response rate
Study contacts
Contact information is provided by the study sponsor or research team.
Nong Yang, MD
CONTACT
+8613055193557 ext. +8613873123436
Yongchang Zhang, MD
CONTACT
+8613873123436 ext. 7+861383123436
Sponsors and collaborators
Lead sponsor
Hunan Province Tumor Hospital
Other
Registry information
Official study title
Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer
Important dates
- Study start
- 2020
- Primary completion
- 2024
- Study completion
- 2025
- First posted
- Mar 27, 2020
- Registry last updated
- Sep 19, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer
NCT06540196
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hamilton, Ontario, Canada
View Trial Details
Recruiting
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
NCT06694454
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bethesda, Maryland, United States
View Trial Details
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846
Bronchial Neoplasms, Carcinoma, Bronchogenic
Birmingham, Alabama, United States
View Trial Details
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664
Breast Diseases, Breast Neoplasms
Margate, Florida, United States
View Trial Details